Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

How well paid are pharma execs? Best in healthcare, survey shows

How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out--and the answer is that drugmakers pay their top managers more than in any other slice of the healthcare industry.

FTC scores hefty $1.2B settlement in Teva pay-for-delay case

After pursuing a pay-for-delay case against Teva's Cephalon unit for years, the Federal Trade Commission has forced the drugmaker to hand over $1.2 billion in past profits.

Novartis, Celgene meds take the biggest shares of cancer drug spending

Cancer drug spending is up. Cancer drug prices are way up. And as a new Express Scripts report shows, spending on each cancer patient is mounting; it's among the reasons why a growing number of individual patients account for $100,000-plus in annual drug spending. And a few big drugs made big contributions to that rise.

Lower-cost Praluent dose may be Sanofi's weapon against Amgen's rival PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters expected to be a pricey proposition.

Happy anniversary? Taking stock at Pfizer, AstraZeneca one year after the mega-mega-deal collapse

One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.

Express Scripts pushes pay-for-performance to cut cancer drug prices

Pay for performance is a byword in executive pay. It's not unprecedented in pharma, what with European cost watchdogs and their hard line against pricey cancer meds. But it's not part of the drug-coverage equation in the U.S.--for now.

Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline

Get ready for a showdown in the irritable bowel syndrome market.

GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze prices

When China said it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But as Bloomberg reports, the optimism may have been premature. Yes, the price caps won't affect most drugs beginning June 1. But foreign drugmakers are facing pressure to cut their prices voluntarily--more than ever.

California's pharma-friendly copay caps could spread to other states

It's official: California's state insurance exchange has capped drug copays. After weighing the new policy for months, Covered California slapped a $250 monthly copay cap on specialty meds, with specific limits on some drugs in some plans ranging from $150 to $500.

CVS Health gets more drug pricing clout with $12B deal for Omnicare

Get ready for more of a squeeze on drugs used by seniors. CVS Health agreed to pay $12.7 billion for the pharmacy services company Omnicare, which specializes in assisted living and long-term care facilities.